Breaking News
Splenectomy as Treatment for Primary Warm Autoimmune Hemolytic Anemia (wAIHA)
WHAT YOU NEED TO KNOW | EMA Recommends Suspension of Pfizer’s Sickle Cell Disease Drug Oxbryta
APLASTIC ANEMIA | Hetrombopag Achieves Significant Hematological Responses in Newly Diagnosed Patients
THALASSAEMIA WEBINAR FOR ASEAN & OCEANIA HEALTHCARE PROFESSIONALS | 21 October 2024
UNITING EXPERTS | Highlights from the 1st Nordic Red Blood Cell Meeting
ANNUAL REPORT 2023 | Unveiling TIF’s Impactful Achievements
WORLD PATIENT SAFETY DAY 2024 | Get It Right, Make It Safe!
REGULATORY APPROVAL | PiaSky Becomes the First Monthly Treatment for PNH in the EU
ACCESS TO INNOVATION | UK Greenlights Gene-Editing Therapy Casgevy for β-Thalassaemia Treatment
GLOBAL SURVEY | Understanding the Thalassaemia Community Health Literacy & Its Impact on Care
English
Italiano
العربية
English
Ελληνικά
Français
Deutsch
Menu
Home
Who we are
TIF History
Vision & Mission
Pillars of Work
Board of Directors
Staff Members
TIF Members
Collaborations
Transparency
Awards & Honours
What we do
Education
Country Work
Projects
Global Thalassaemia Review
COVID-19 Pandemic
Surveys
Haemoglobin Disorders
Thalassaemia
Sickle Cell Disease
Clinical Trial Updates
Positions & Policies
Policy Framework
Position Papers
Official Statements
Publications
TIF Publications
Scientific Literature
Additional Resources
Media Centre
News
Newsletters
Events
Videos
Contact us
Search for
Home
/
AtRisk
AtRisk
Press Releases
October 20, 2021
TIF Supports Administration Of COVID-19 Vaccine Booster Dose To Patients With Haemoglobin Disorders
Read More »
Back to top button
Close
Search for
